Ulla Vanleeuw
Leuven, VLG, Belgium
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Antitumor activity of novel transcriptional inhibitors ecubectedin and PM54 in soft tissue sarcoma patient-derived xenografts.
Journal: Cancer research communications
Published: May 25, 2026
Molecular epidemiology of the expression of urokinase plasminogen activator receptor-associated protein (uPARAP) in mesenchymal malignancies.
Journal: Translational oncology
Published: September 15, 2025
Urokinase Plasminogen Activator Receptor-Associated Protein (uPARAP) as a Potential Next Generation Molecular Target for Treatment of Gastrointestinal Stromal Tumors (GIST).
Journal: International journal of cancer
Published: May 12, 2025
Patient-derived xenograft models of gastrointestinal stromal tumors provide a ready-to-use platform for translational research.
Journal: Disease models & mechanisms
Published: June 12, 2024
Potentially actionable targets in synovial sarcoma: A tissue microarray study.
Journal: Translational oncology
Published: May 03, 2024
Antitumor Efficacy of the Novel KIT Inhibitor IDRX-42 (Formerly M4205) in Patient- and Cell Line-Derived Xenograft Models of Gastrointestinal Stromal Tumor (GIST).
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 24, 2022
Enhanced Antitumor Efficacy of PhAc-ALGP-Dox, an Enzyme-Activated Doxorubicin Prodrug, in a Panel of THOP1-Expressing Patient-Derived Xenografts of Soft Tissue Sarcoma.
Journal: Biomedicines
Published: February 22, 2022
Establishment of an Academic Tissue Microarray Platform as a Tool for Soft Tissue Sarcoma Research.
Journal: Sarcoma
Published: December 01, 2020
Establishment and Characterization of Histologically and Molecularly Stable Soft-tissue Sarcoma Xenograft Models for Biological Studies and Preclinical Drug Testing.
Journal: Molecular cancer therapeutics
Published: September 13, 2018
Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 13, 2018
In Vivo Antitumoral Efficacy of PhAc-ALGP-Doxorubicin, an Enzyme-Activated Doxorubicin Prodrug, in Patient-Derived Soft Tissue Sarcoma Xenograft Models.
Journal: Molecular cancer therapeutics
Published: December 05, 2016
Cabozantinib Is Active against Human Gastrointestinal Stromal Tumor Xenografts Carrying Different KIT Mutations.
Journal: Molecular cancer therapeutics
Published: April 11, 2016
Last Updated: 09/26/2026